Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03196167 · ClinicalTrials.gov registry record · Phase 4
Sugammadex and Decreased Time to Extubation
A Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT03196167 is a Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery that has completed, run by Yale University. The registered enrollment target is 90 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03196167, a Phase 4 study of Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate faster time to extubation after arrival in the cardiothoracic intensive care unit (ICU) in patients undergoing isolated coronary artery bypass grafting (CABG), AVR and AVR/CABG combination who receive Sugammadex as compared to placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Sugammadex
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2017-05-13 |
| Est. Completion | 2020-10-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03196167
The ClinicalTrials.gov registry entry for NCT03196167 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03196167 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT03196167 about?
NCT03196167 is a clinical study titled "Sugammadex and Decreased Time to Extubation". The purpose of this study is to demonstrate faster time to extubation after arrival in the cardiothoracic intensive care unit (ICU) in patients undergoing isolated coronary artery bypass grafting (CABG), AVR and AVR/CABG combination who receive Sugammadex as compared to placebo.
What is the current status of trial NCT03196167?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2017-05-13. Estimated completion is 2020-10-10.
What conditions does trial NCT03196167 study?
This clinical trial studies the following conditions: Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery.
What interventions are being tested in trial NCT03196167?
The interventions under investigation include: Placebo (OTHER), Sugammadex (DRUG).
Who is sponsoring clinical trial NCT03196167?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03196167 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.